Who
Barclay A. Phillips
Director
Company insider
Files Form 4 as: Director, Immunic; SVP & Chief Financial Officer, G1 Therapeutics; SVP, Chief Financial Officer, Novavax; SVP, CFO, Micromet; Director, Acorda Therapeutics.
In numbers
- Trades disclosed
- 114
- Buys
- 14
- Sells
- 5
- Bought
- $250K
- Sold
- $7.9M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 15 Feb 2006
- Last trade
- 5 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jul 2026filed 7 Jul 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,370 at $0.00 | filing |
| 5 Jul 2026filed 7 Jul 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,370 at $0.00 | filing |
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,370 at $0.00 | filing |
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,370 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 11 Jun 2024filed 12 Jun 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,973 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,986 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,959 | filing |
| 28 Jun 2023filed 29 Jun 2023 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 2 Jul 2020filed 6 Jul 2020 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 18 Nov 2019filed 19 Nov 2019 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,959 at $0.00 | filing |
| 2 Jan 2019filed 2 Jan 2019 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 15 Nov 2018filed 16 Nov 2018 | G1 Therapeutics | SEC FORM 4 Code M | $97K5,000 at $19.46 | filing |
| 15 Nov 2018filed 16 Nov 2018 | G1 Therapeutics | SEC FORM 4 Sold | $200K5,000 at $39.92 | filing |
News
Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)NVAX · themarketsdaily.com · 11 Oct 2026Novavax (NASDAQ:NVAX) Sees Large Volume Increase – Should You Buy?NVAX · dailypolitical.com · 9 Oct 2026
0 headlines in the last 90 days name Barclay A. Phillips; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.